Sparreboom A - Search Results

1

Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib.

van Erp NP, Gelderblom H, Karlsson MO, Li J, Zhao M, Ouwerkerk J, Nortier JW, Guchelaar HJ, Baker SD, Sparreboom A. van Erp NP, et al. Among authors: sparreboom a. Clin Cancer Res. 2007 Dec 15;13(24):7394-400. doi: 10.1158/1078-0432.CCR-07-0346. Clin Cancer Res. 2007. PMID: 18094422 Clinical Trial.

2

Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.

Sparreboom A, de Jonge MJ, Punt CJ, Nooter K, Loos WJ, Porro MG, Verweij J. Sparreboom A, et al. Clin Cancer Res. 1998 Aug;4(8):1915-9. Clin Cancer Res. 1998. PMID: 9717819 Clinical Trial.

3

Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J. Sparreboom A, et al. Cancer Res. 1999 Apr 1;59(7):1454-7. Cancer Res. 1999. PMID: 10197613

4

Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.

Gelderblom H, Verweij J, Brouwer E, Pillay M, de Bruijn P, Nooter K, Stoter G, Sparreboom A. Gelderblom H, et al. Among authors: sparreboom a. Drug Metab Dispos. 1999 Nov;27(11):1300-5. Drug Metab Dispos. 1999. PMID: 10534315

5

Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.

van Tellingen O, Beijnen JH, Verweij J, Scherrenburg EJ, Nooijen WJ, Sparreboom A. van Tellingen O, et al. Among authors: sparreboom a. Clin Cancer Res. 1999 Oct;5(10):2918-24. Clin Cancer Res. 1999. PMID: 10537361

6

Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans.

Loos WJ, Verweij J, Gelderblom HJ, de Jonge MJ, Brouwer E, Dallaire BK, Sparreboom A. Loos WJ, et al. Among authors: sparreboom a. Anticancer Drugs. 1999 Sep;10(8):705-10. doi: 10.1097/00001813-199909000-00003. Anticancer Drugs. 1999. PMID: 10573202 Clinical Trial.

7

Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor.

Eskens FA, Levitt NC, Sparreboom A, Choi L, Mather R, Verweij J, Harris AL. Eskens FA, et al. Among authors: sparreboom a. Clin Cancer Res. 2000 Feb;6(2):431-3. Clin Cancer Res. 2000. PMID: 10690520 Clinical Trial.

8

Oral topoisomerase 1 inhibitors in adult patients: present and future.

Gelderblom HA, DE Jonge MJ, Sparreboom A, Verweij J. Gelderblom HA, et al. Among authors: sparreboom a. Invest New Drugs. 1999;17(4):401-15. doi: 10.1023/a:1006394610219. Invest New Drugs. 1999. PMID: 10759406 Review.

9

Topotecan lacks third space sequestration.

Gelderblom H, Loos WJ, Verweij J, de Jonge MJ, Sparreboom A. Gelderblom H, et al. Among authors: sparreboom a. Clin Cancer Res. 2000 Apr;6(4):1288-92. Clin Cancer Res. 2000. PMID: 10778953 Clinical Trial.

10

The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.

van Zuylen L, Sparreboom A, van der Gaast A, van der Burg ME, van Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij J. van Zuylen L, et al. Among authors: sparreboom a. Clin Cancer Res. 2000 Apr;6(4):1365-71. Clin Cancer Res. 2000. PMID: 10778964 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

389 results

Search Page

Filters